<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="549">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500225</url>
  </required_header>
  <id_info>
    <org_study_id>Ulku 1</org_study_id>
    <nct_id>NCT02500225</nct_id>
  </id_info>
  <brief_title>Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy</brief_title>
  <official_title>Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to investigate the effects of etomidate or sevoflurane used in
      electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery
      profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-five patients will be a total of 150 ECT treatments in this prospective,
      double-blinded, crossover study. Each patient will receive either 0.2 mg/kg etomidate (Group
      1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of
      consciousness for their initial electroconvulsive therapy session. In subsequent sessions,
      patients will receive the alternative sevoflurane concentration and then alternated between
      doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine.
      Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean
      arterial pressure (MAP) values, and recovery times will recorde.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Motor (EMG) seizure duration</measure>
    <time_frame>intraoperative</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>electroencephalography (EEG) seizure duration</measure>
    <time_frame>intraoperative</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate (HR),</measure>
    <time_frame>(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial pressure (MAP)</measure>
    <time_frame>(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MAP will be measured by a blood pressure cuff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recovery times</measure>
    <time_frame>(approximately 5 minutes for all measurements) prior to the seizure, after the anesthetic induction, and following the ECT session at 1 minute, 3 minutes, and 10 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Recovery times will be assessed with spontaneous breathing, eye opening, obeying commands times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Anesthesia</condition>
  <condition>ECT</condition>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2 mg/kg etomidate during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8% sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane 8% concentration during anesthesia induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>0.2 mg/kg etomidate</description>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_label>8% sevoflurane</arm_group_label>
    <other_name>Hypnomidate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>8% Sevoflurane</description>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_label>8% sevoflurane</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study include 25 patients of American Society of Anesthesiologists (ASA) physical
             status I-II aged between 18-60 years who schedule for ECT sessions under general
             anesthesia

        Exclusion Criteria:

          -  Pregnancy

          -  Cerebrovascular disease

          -  Epilepsy

          -  Unstable cardiovascular disease

          -  Chronic obstructive pulmonary disease; and

          -  Renal or hepatic failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulku Ozgul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inonu University School of Medicine</affiliation>
  </overall_official>
  <results_reference>
    <citation>Janouschek H, Nickl-Jockschat T, Haeck M, Gillmann B, Grözinger M. Comparison of methohexital and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders. J Psychiatr Res. 2013 May;47(5):686-93. doi: 10.1016/j.jpsychires.2012.12.019. Epub 2013 Feb 9.</citation>
    <PMID>23399487</PMID>
  </results_reference>
  <results_reference>
    <citation>Toprak HI, Gedik E, Begeç Z, Oztürk E, Kaya B, Ersoy MO. Sevoflurane as an alternative anaesthetic for electroconvulsive therapy. J ECT. 2005 Jun;21(2):108-10.</citation>
    <PMID>15905753</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 15, 2015</lastchanged_date>
  <firstreceived_date>July 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Ülkü Özgül</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Etomidate</keyword>
  <keyword>Sevoflurane</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
